Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Palatin Technologies, Inc. (PTNT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PTNT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
Analysis of Past Performance
Type Stock | Historic Profit -17.8% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.04 - 1.96 | Updated Date 06/3/2025 |
52 Weeks Range 0.04 - 1.96 | Updated Date 06/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Palatin Technologies, Inc.
Company Overview
History and Background
Palatin Technologies, Inc. is a biopharmaceutical company founded in 1986. Initially focused on peptide technologies, it has evolved to concentrate on developing targeted, receptor-specific therapeutics for diseases with significant unmet medical needs. The company went public in 1992.
Core Business Areas
- Melanocortin Receptor (MCR) Programs: Development of peptide therapeutics targeting melanocortin receptors (MCRs), with a focus on sexual dysfunction, inflammatory conditions, and obesity.
Leadership and Structure
Carl Spana is the President and CEO. The company has a board of directors overseeing strategic direction. It operates with a functional organizational structure, with departments for research, development, clinical trials, and commercial operations.
Top Products and Market Share
Key Offerings
- Vyleesi (bremelanotide): Vyleesi is an injectable treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. It targets melanocortin receptors. Palatin licensed the North American rights to Vyleesi to Cosette Pharmaceuticals. While Palatin doesn't directly have market share, Vyleesi faces competition from Addyi (flibanserin), marketed by Sprout Pharmaceuticals, and other lifestyle changes.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. The market for sexual dysfunction treatments is growing, with increasing awareness and acceptance. Developments in women's health and novel drug delivery are key trends.
Positioning
Palatin Technologies focuses on developing receptor-specific therapeutics. They position themselves as innovators in melanocortin receptor pharmacology, targeting niche markets with unmet needs. Their competitive advantage lies in their expertise in peptide-based drug development.
Total Addressable Market (TAM)
The TAM for HSDD treatments is estimated to be in the billions of dollars annually. Palatin, through its partnered drug Vyleesi, is positioned to capture a portion of this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary melanocortin receptor technology
- Experienced management team
- Strong patent portfolio (though subject to expiration)
- Collaboration with Cosette Pharmaceuticals for Vyleesi
Weaknesses
- Reliance on single product (Vyleesi) for revenue
- Limited financial resources
- Competition in the sexual dysfunction market
- Dependence on partners for commercialization
Opportunities
- Expansion of Vyleesi indications
- Development of new melanocortin receptor-based therapeutics
- Partnerships with larger pharmaceutical companies
- Growth in the women's health market
Threats
- Competition from existing and new HSDD treatments
- Regulatory hurdles
- Patent expiration
- Market acceptance of Vyleesi
- Potential failure of clinical trials for other pipeline products
Competitors and Market Share
Key Competitors
- AMAG
- VRX
Competitive Landscape
Palatin is a smaller player competing with larger pharmaceutical companies. Their advantage lies in their expertise in melanocortin receptor pharmacology. Disadvantages include limited resources and dependence on partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the launch of Vyleesi. Consult financial reports for specific growth rates.
Future Projections: Future projections depend on the success of Vyleesi and pipeline development. Analyst estimates should be consulted.
Recent Initiatives: Palatin Technologies focuses on developing new MCR-based therapeutics. They have several early stage studies. Their recent initiatives can be seen in their annual and quarterly filings.
Summary
Palatin Technologies is a biopharmaceutical company focused on developing MCR-based therapeutics. They are dependent on royalties from Vyleesi and face strong competition in the sexual dysfunction market. Their strength lies in their expertise in MCR pharmacology, while weaknesses include limited resources. The company needs to expand its pipeline and secure additional partnerships for sustainable growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Palatin Technologies, Inc.
Exchange NASDAQ | Headquaters Cranbury, NJ, United States | ||
IPO Launch date - | Co-Founder, President, CEO & Director Dr. Carl Spana Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://palatin.com |
Full time employees 30 | Website https://palatin.com | ||
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.